NEORX CORP
10-Q, EX-27, 2000-11-13
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: NEORX CORP, 10-Q, EX-10.4, 2000-11-13
Next: KFP 85 LTD, 10-Q, 2000-11-13



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM 9/30/00
10(Q) AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           4,379
<SECURITIES>                                    57,322
<RECEIVABLES>                                      250
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                62,655
<PP&E>                                           8,887
<DEPRECIATION>                                   7,673
<TOTAL-ASSETS>                                  64,570
<CURRENT-LIABILITIES>                            1,568
<BONDS>                                              0
                                0
                                          4
<COMMON>                                           522
<OTHER-SE>                                      62,476
<TOTAL-LIABILITY-AND-EQUITY>                    64,570
<SALES>                                              0
<TOTAL-REVENUES>                                 1,588
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                16,005
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  48
<INCOME-PRETAX>                                (9,671)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (9,671)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (9,671)
<EPS-BASIC>                                     (0.44)
<EPS-DILUTED>                                   (0.44)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission